O	0	9	Treatment
O	10	14	with
B-intervention	15	19	Ruta
I-intervention	20	30	graveolens
I-intervention	31	34	5CH
I-intervention	35	38	and
I-intervention	39	43	Rhus
I-intervention	44	57	toxicodendron
I-intervention	58	61	9CH
O	62	65	may
O	66	72	reduce
B-condition	73	78	joint
I-condition	79	83	pain
I-condition	84	87	and
I-condition	88	97	stiffness
O	98	104	linked
O	105	107	to
O	108	117	aromatase
O	118	128	inhibitors
O	129	131	in
B-eligibility	132	137	women
I-eligibility	138	142	with
I-eligibility	143	148	early
I-eligibility	149	155	breast
I-eligibility	156	162	cancer
O	162	163	:
O	164	171	results
O	172	174	of
O	175	176	a
O	177	182	pilot
O	183	196	observational
O	197	202	study
O	202	203	.

O	204	206	To
O	207	216	determine
O	217	220	the
O	221	229	possible
O	230	236	effect
O	237	239	of
O	240	243	two
O	244	255	homeopathic
O	256	265	medicines
O	265	266	,
O	267	271	Ruta
O	272	282	graveolens
O	283	286	5CH
O	287	290	and
O	291	295	Rhus
O	296	309	toxicodendron
O	310	313	9CH
O	313	314	,
O	315	317	in
O	318	321	the
O	322	332	prevention
O	333	335	of
O	336	345	aromatase
O	346	355	inhibitor
O	356	357	(
O	357	359	AI
O	359	360	)
O	361	371	associated
O	372	377	joint
O	378	382	pain
O	383	386	and
O	386	387	/
O	387	389	or
O	390	399	stiffness
O	400	402	in
B-eligibility	403	408	women
I-eligibility	409	413	with
I-eligibility	414	419	early
I-eligibility	419	420	,
I-eligibility	421	428	hormone
I-eligibility	428	429	-
I-eligibility	429	437	receptor
I-eligibility	438	446	positive
I-eligibility	446	447	,
I-eligibility	448	454	breast
I-eligibility	455	461	cancer
O	461	462	.

O	463	467	This
O	468	479	prospective
O	479	480	,
O	481	493	unrandomized
O	494	507	observational
O	508	513	study
O	514	517	was
O	518	525	carried
O	526	529	out
O	530	537	between
O	538	543	April
O	544	547	and
O	548	555	October
O	556	560	2014
O	560	561	.

O	562	567	Women
O	568	572	were
O	573	582	recruited
O	583	585	in
O	586	589	two
O	590	596	groups
O	596	597	,
O	598	607	according
O	608	610	to
O	611	616	which
O	617	619	of
O	620	623	the
O	624	627	two
O	628	633	study
O	634	641	centres
O	642	646	they
O	647	655	attended
O	655	656	:
O	657	660	one
O	661	670	receiving
O	671	681	homeopathy
O	682	684	in
O	685	693	addition
O	694	696	to
O	697	705	standard
O	706	715	treatment
O	716	717	(
O	717	722	group
O	723	724	H
O	724	725	)
O	726	729	and
O	730	731	a
O	732	739	control
O	740	745	group
O	745	746	,
O	747	756	receiving
B-control	757	765	standard
I-control	766	775	treatment
O	776	777	(
O	777	782	group
O	783	784	C
O	784	785	)
O	785	786	.

O	787	790	All
O	791	796	women
O	797	801	were
O	802	809	treated
O	810	814	with
O	815	817	an
O	818	820	AI
O	820	821	.

O	822	824	In
O	825	833	addition
O	833	834	,
O	835	840	women
O	841	843	in
O	844	849	group
O	850	851	H
O	852	856	also
O	857	861	took
O	862	866	Ruta
O	867	877	graveolens
O	878	881	5CH
O	882	885	and
O	886	890	Rhus
O	891	904	toxicodendron
O	905	908	9CH
O	909	910	(
O	910	911	5
O	912	920	granules
O	920	921	,
O	922	927	twice
O	928	929	a
O	930	933	day
O	933	934	)
O	935	937	up
O	938	940	to
O	941	942	7
O	943	947	days
O	948	954	before
O	955	963	starting
O	964	966	AI
O	967	976	treatment
O	976	977	.

O	978	981	The
O	982	993	homeopathic
O	994	1003	medicines
O	1004	1008	were
O	1009	1018	continued
O	1019	1022	for
O	1023	1024	3
O	1025	1031	months
O	1031	1032	.

O	1033	1044	Demographic
O	1045	1048	and
O	1049	1057	clinical
O	1058	1062	data
O	1063	1067	were
O	1068	1076	recorded
O	1077	1082	using
O	1083	1084	a
O	1085	1089	self
O	1089	1090	-
O	1090	1100	assessment
O	1101	1114	questionnaire
O	1115	1117	at
O	1118	1127	inclusion
O	1128	1129	(
O	1129	1131	T0
O	1131	1132	)
O	1133	1136	and
O	1137	1138	3
O	1139	1145	months
O	1146	1147	(
O	1147	1149	T3
O	1149	1150	)
O	1150	1151	.

O	1152	1159	Primary
O	1160	1170	evaluation
O	1171	1179	criteria
O	1180	1184	were
O	1185	1188	the
B-outcome-Measure	1189	1198	evolution
I-outcome-Measure	1199	1201	of
I-outcome-Measure	1202	1208	scores
I-outcome-Measure	1209	1212	for
I-outcome-Measure	1213	1218	joint
I-outcome-Measure	1219	1223	pain
I-outcome-Measure	1224	1227	and
I-outcome-Measure	1228	1237	stiffness
O	1237	1238	,
O	1239	1242	the
B-outcome-Measure	1243	1249	impact
I-outcome-Measure	1250	1252	of
I-outcome-Measure	1253	1257	pain
I-outcome-Measure	1258	1260	on
I-outcome-Measure	1261	1266	sleep
I-outcome-Measure	1267	1270	and
I-outcome-Measure	1271	1280	analgesic
I-outcome-Measure	1281	1292	consumption
O	1293	1295	in
O	1296	1299	the
O	1300	1303	two
O	1304	1310	groups
O	1311	1316	after
O	1317	1318	3
O	1319	1325	months
O	1326	1328	of
O	1329	1338	treatment
O	1338	1339	.

B-total-participants	1340	1345	Forty
O	1346	1354	patients
O	1355	1356	(
O	1356	1360	mean
O	1361	1364	age
B-age	1365	1367	64
I-age	1367	1368	.
I-age	1368	1369	9
I-age	1369	1370	±
I-age	1370	1371	8
I-age	1371	1372	.
I-age	1372	1373	1
I-age	1374	1379	years
O	1379	1380	)
O	1381	1385	were
O	1386	1395	recruited
O	1395	1396	,
B-intervention-participants	1397	1399	20
O	1400	1402	in
O	1403	1407	each
O	1408	1413	group
O	1413	1414	.

O	1415	1418	Two
O	1418	1419	-
O	1419	1425	thirds
O	1426	1428	of
O	1429	1432	the
O	1433	1441	patients
O	1442	1445	had
O	1446	1451	joint
O	1452	1456	pain
O	1457	1463	before
O	1464	1472	starting
O	1473	1475	AI
O	1476	1485	treatment
O	1485	1486	.

O	1487	1492	There
O	1493	1496	was
O	1497	1498	a
O	1499	1510	significant
O	1511	1521	difference
O	1522	1524	in
O	1525	1528	the
B-outcome	1529	1538	evolution
I-outcome	1539	1541	of
I-outcome	1542	1546	mean
I-outcome	1547	1556	composite
I-outcome	1557	1561	pain
I-outcome	1562	1567	score
O	1568	1575	between
O	1576	1578	T0
O	1579	1582	and
O	1583	1585	T3
O	1586	1588	in
O	1589	1592	the
O	1593	1596	two
O	1597	1603	groups
O	1604	1605	(
B-iv-cont-mean	1605	1606	-
I-iv-cont-mean	1606	1607	1
I-iv-cont-mean	1607	1608	.
I-iv-cont-mean	1608	1609	3
O	1610	1612	in
O	1613	1618	group
O	1619	1620	H
O	1621	1623	vs
O	1623	1624	.
B-cv-cont-mean	1625	1626	+
I-cv-cont-mean	1626	1627	3
I-cv-cont-mean	1627	1628	.
I-cv-cont-mean	1628	1629	4
O	1630	1632	in
O	1633	1638	group
O	1639	1640	C
O	1640	1641	;
O	1642	1643	p
O	1643	1644	=
O	1644	1645	0
O	1645	1646	.
O	1646	1650	0001
O	1650	1651	)
O	1651	1652	.

O	1653	1656	The
B-outcome	1657	1667	individual
I-outcome	1668	1678	components
I-outcome	1679	1681	of
I-outcome	1682	1685	the
I-outcome	1686	1690	pain
I-outcome	1691	1696	score
O	1697	1698	(
O	1698	1707	frequency
O	1707	1708	,
O	1709	1718	intensity
O	1719	1722	and
O	1723	1729	number
O	1730	1732	of
O	1733	1738	sites
O	1739	1741	of
O	1742	1746	pain
O	1746	1747	)
O	1748	1752	also
O	1753	1762	decreased
O	1763	1776	significantly
O	1777	1779	in
O	1780	1785	group
O	1786	1787	H
O	1787	1788	.

B-cv-bin-abs	1789	1793	Nine
O	1794	1802	patients
O	1803	1805	in
O	1806	1811	group
O	1812	1813	C
O	1814	1815	(
B-cv-bin-percent	1815	1817	45
I-cv-bin-percent	1817	1818	%
O	1818	1819	)
O	1820	1822	vs
O	1822	1823	.
B-iv-bin-abs	1824	1825	1
O	1826	1827	(
B-iv-bin-percent	1827	1828	5
I-iv-bin-percent	1828	1829	%
O	1829	1830	)
O	1831	1833	in
O	1834	1839	group
O	1840	1841	H
O	1842	1851	increased
O	1852	1857	their
B-outcome	1858	1867	analgesic
I-outcome	1868	1879	consumption
O	1880	1887	between
O	1888	1890	T0
O	1891	1894	and
O	1895	1897	T3
O	1898	1899	(
O	1899	1900	p
O	1900	1901	=
O	1901	1902	0
O	1902	1903	.
O	1903	1907	0076
O	1907	1908	)
O	1908	1909	.

O	1910	1915	After
O	1916	1917	3
O	1918	1924	months
O	1925	1927	of
O	1928	1937	treatment
O	1937	1938	,
B-outcome	1939	1944	joint
I-outcome	1945	1949	pain
I-outcome	1950	1953	had
I-outcome	1954	1955	a
I-outcome	1956	1961	worse
I-outcome	1962	1968	impact
I-outcome	1969	1971	on
I-outcome	1972	1977	sleep
O	1978	1980	in
O	1981	1989	patients
O	1990	1992	in
O	1993	1998	group
O	1999	2000	C
O	2001	2002	(
B-cv-bin-percent	2002	2004	35
I-cv-bin-percent	2004	2005	%
O	2006	2008	vs
O	2008	2009	.
B-iv-bin-percent	2010	2011	0
I-iv-bin-percent	2011	2012	%
O	2013	2015	of
O	2016	2024	patients
O	2024	2025	;
O	2026	2027	p
O	2027	2028	=
O	2028	2029	0
O	2029	2030	.
O	2030	2034	0083
O	2034	2035	)
O	2035	2036	.

O	2037	2040	The
O	2041	2052	differences
O	2053	2061	observed
O	2062	2064	in
O	2065	2068	the
B-outcome	2069	2078	evolution
I-outcome	2079	2081	of
I-outcome	2082	2089	morning
I-outcome	2090	2093	and
I-outcome	2094	2101	daytime
I-outcome	2102	2111	stiffness
O	2112	2119	between
O	2120	2123	the
O	2124	2127	two
O	2128	2134	groups
O	2135	2139	were
O	2140	2147	smaller
O	2148	2149	(
O	2149	2150	p
O	2150	2151	=
O	2151	2152	0
O	2152	2153	.
O	2153	2156	053
O	2157	2160	and
O	2161	2162	p
O	2162	2163	=
O	2163	2164	0
O	2164	2165	.
O	2165	2167	33
O	2167	2168	,
O	2169	2181	respectively
O	2181	2182	)
O	2182	2183	,
O	2184	2188	with
O	2189	2192	the
O	2193	2202	exception
O	2203	2205	of
O	2206	2210	time
O	2211	2220	necessary
O	2221	2224	for
O	2225	2228	the
O	2229	2242	disappearance
O	2243	2245	of
O	2246	2253	morning
O	2254	2263	stiffness
O	2264	2269	which
O	2270	2273	was
O	2274	2281	greater
O	2282	2284	in
O	2285	2290	group
O	2291	2292	C
O	2293	2294	(
B-iv-cont-mean	2294	2296	37
I-iv-cont-mean	2296	2297	.
I-iv-cont-mean	2297	2298	7
O	2298	2299	±
B-iv-cont-sd	2299	2301	23
I-iv-cont-sd	2301	2302	.
I-iv-cont-sd	2302	2303	0
O	2304	2306	vs
O	2306	2307	.
B-cv-cont-mean	2308	2310	17
I-cv-cont-mean	2310	2311	.
I-cv-cont-mean	2311	2312	9
O	2312	2313	±
B-cv-cont-sd	2313	2315	20
I-cv-cont-sd	2315	2316	.
I-cv-cont-sd	2316	2317	1
I-cv-cont-sd	2318	2321	min
O	2321	2322	;
O	2323	2324	p
O	2324	2325	=
O	2325	2326	0
O	2326	2327	.
O	2327	2331	0173
O	2331	2332	)
O	2332	2333	.

O	2334	2339	These
O	2340	2351	preliminary
O	2352	2359	results
O	2360	2367	suggest
O	2368	2372	that
O	2373	2382	treatment
O	2383	2387	with
O	2388	2392	Ruta
O	2393	2403	graveolens
O	2404	2407	5CH
O	2408	2411	and
O	2412	2416	Rhus
O	2417	2430	toxicodendron
O	2431	2434	9CH
O	2435	2438	may
O	2439	2447	decrease
O	2448	2453	joint
O	2454	2458	pain
O	2458	2459	/
O	2459	2468	stiffness
O	2469	2471	in
O	2472	2478	breast
O	2479	2485	cancer
O	2486	2494	patients
O	2495	2502	treated
O	2503	2507	with
O	2508	2511	AIs
O	2511	2512	.

O	2513	2514	A
O	2515	2521	larger
O	2521	2522	-
O	2522	2527	scale
O	2528	2538	randomized
O	2539	2544	study
O	2545	2547	is
O	2548	2556	required
O	2557	2559	to
O	2560	2567	confirm
O	2568	2573	these
O	2574	2581	results
O	2581	2582	.
